证券代码：000710 证券简称：贝瑞基因 公告编号：2025-026 成都市贝瑞和康基因技术股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、会议召开情况 1、会议时间： （1）现场会议召开时间：2025年5月20日（星期二）14:30 6、本次股东大会符合有关法律、行政法规、部门规章、规范性文件、深圳证券 交易所业务规则和公司章程等的规定。 7、股东出席会议情况 本次出席现场会议的股东2人，代表股份45,773,798股，占公司有表决权股份总 数的12.9480%。 （2）网络投票时间：其中，通过深圳证券交易所交易系统进行网络投票的具体 时间为2025年5月20日9:15—9:25、9:30—11:30、13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年5月20日9:15— 15:00。 2、会议地点：北京市昌平区生命园路4号院5号楼公司6层会议室 3、会议召开方式： 本次股东大会采用现场表决与网络投票相结合的方式。本公司通过深圳证券交 易所交易系统和互联网投票系统（htt ...

之法律意见书 致：成都市贝瑞和康基因技术股份有限公司 北京市金杜律师事务所（以下简称本所）接受成都市贝瑞和康基因技术股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督 管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共 和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章 和规范性文件和现行有效的公司章程有关规定，指派律师现场出席了公司于 2025 年 5 月 20 日召开的 2024 年年度股东大会（以下简称本次股东大会），并 就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2023 年年度股东大会审议通过的《成都市贝瑞和康基因技术股份 有限公司章程》（以下简称《公司章程》）； 北京市金杜律师事务所 关于成都市贝瑞和康基因技术股份有限公司 2024 年年度股东大会 2. 公司 2025 年 4 月 25 日刊登于《中国证券报 ...

Core Viewpoint - The forced liquidation of shares held by the controlling shareholder, Gao Yang, due to a default in a stock pledge repurchase agreement, raises concerns about the financial stability of Berry Genomics and its declining stock price [1][2][5] Group 1: Shareholder Actions and Impacts - Gao Yang, the founder and chairman of Berry Genomics, has had 3,535,214 shares (1% of total shares) ordered for forced liquidation due to a default on a stock pledge with Guosen Securities [1] - All shares held by Gao Yang (9.05% of total shares) are currently under judicial freeze, indicating significant financial distress [3] - The forced execution of shares is part of a broader trend where both Gao Yang and his associate, Hou Ying, have seen their shares subjected to judicial auction due to ongoing financial difficulties [4] Group 2: Financial Performance - Berry Genomics has experienced a continuous decline in revenue and has reported losses for four consecutive years, totaling approximately 9.85 billion yuan [5] - The company's revenue figures from 2021 to 2024 are approximately 14.22 billion yuan, 13.68 billion yuan, 11.51 billion yuan, and 10.78 billion yuan, respectively, with net profits turning negative starting in 2021 [5] - The decline in performance is attributed to market demand changes and increased competition, leading to significant asset impairment provisions [5] Group 3: Stock Performance - The stock price of Berry Genomics has plummeted from a peak of 98 yuan per share in July 2020 to below 10 yuan per share in 2023, reflecting a severe loss of investor confidence [2] - As of May 19, the stock closed at 13.40 yuan per share, down 5.57% [5]

Core Viewpoint - The announcement highlights that a significant shareholder of Berry Genomics, Gao Yang, is subject to judicial enforcement regarding the forced liquidation of a portion of his shares due to a breach of contract with Guoxin Securities [1][2]. Group 1: Shareholder and Legal Actions - Gao Yang, the controlling shareholder of Berry Genomics, holds 31,988,723 shares, accounting for 9.05% of the total share capital [1]. - The Chengdu Financial Court has ordered the forced liquidation of 3,535,214 shares held by Gao Yang due to a breach of a stock pledge repurchase agreement with Guoxin Securities [1][2]. - The enforcement action is based on a legally effective arbitration ruling from the Shenzhen International Arbitration Court [1]. Group 2: Financial Performance - Berry Genomics reported net profits attributable to shareholders of -117 million yuan in 2021, -249 million yuan in 2022, -427 million yuan in 2023, and -192 million yuan in 2024 [3]. - The company's operating revenue for 2024 is 1,078 million yuan, a decrease of 6.36% from 2023, which had revenue of 1,151 million yuan [4]. - The net profit attributable to shareholders for 2024 improved by 54.96% compared to 2023, indicating a reduction in losses [4].

成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行的提示性公告 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-025 股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、高扬先生持有成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或 "贝瑞基因"）股份 31,988,723 股（占公司总股本比例为 9.05%），为公司控股股 东。现因高扬先生在国信证券股份有限公司（以下简称"国信证券"）开展的股票质 押回购业务发生违约，成渝金融法院裁定强制变现被执行人高扬先生持有的 3,535,214 股"贝瑞基因"股票。 2、公司目前生产经营情况正常，该事项未对公司的生产经营及财务状况产生重 大不利影响，未对公司治理结构产生重大不利影响。 公司于近日收到股东高扬先生通知，其于近日收到成渝金融法院作出的(2024) 渝 87 执 4703 号之三《执行裁定书》，裁定强制变现被执行人高扬先生持有的 3,535,214 股"贝瑞基因"股票。现将有关情况 ...

资金面上看，今日基因测序概念板块获主力资金净流入4.22亿元，其中，33股获主力资金净流入，10股 主力资金净流入超千万元，净流入资金居首的是贝瑞基因，今日主力资金净流入1.38亿元，净流入资金 居前的还有东方海洋、华大基因、美年健康等，主力资金分别净流入1.31亿元、1.26亿元、3326.88万 元。 截至5月13日收盘，基因测序概念上涨1.23%，位居概念板块涨幅第10，板块内，39股上涨，贝瑞基 因、东方海洋等涨停，华大基因、迪安诊断、华大智造等涨幅居前，分别上涨14.55%、8.27%、 6.89%。跌幅居前的有新芝生物、谱尼测试、茂莱光学等，分别下跌1.66%、1.62%、1.61%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 3.03 | 中船系 | -3.40 | | 航运概念 | 2.51 | 国产航母 | -2.37 | | 硅能源 | 2.30 | 军工信息化 | -2.16 | | 环氧丙烷 | 1.95 | 太赫兹 | -2.14 | | 阿尔茨海默概念 | 1 ...

Group 1 - The core viewpoint of the news highlights the recent performance and market position of Berry Genomics, noting a significant stock price increase and a low market-to-book ratio [1] - On May 13, Berry Genomics closed at 13.96 yuan, up 10.01%, with a market capitalization of 4.935 billion yuan and a price-to-book ratio of 2.96, marking a new low in 31 days [1] - The company experienced a net inflow of 137.79 million yuan in main funds on May 13, with a total inflow of 102.66 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Berry Genomics specializes in gene testing services based on high-throughput sequencing technology, offering related equipment and reagent sales [1] - The company provides comprehensive solutions through "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1] - The latest financial report for Q1 2025 shows the company achieved revenue of 218 million yuan, a year-on-year decrease of 22.08%, with a net loss of approximately 6.46 million yuan, reflecting a year-on-year decline of 178.47% and a gross profit margin of 49.48% [1] Group 3 - In comparison to industry averages, Berry Genomics has a TTM PE ratio of -23.83 and a static PE ratio of -25.65, with a market capitalization of 4.935 billion yuan [2] - The industry average PE ratios are significantly higher, with the average TTM PE at 50.06 and the static PE at 45.92, indicating that Berry Genomics is underperforming relative to its peers [2] - The industry median market capitalization is 4.795 billion yuan, suggesting that Berry Genomics is positioned within a competitive landscape [2]

医药行业周报 关注血透、药房等细分领域投资机遇 2025 年 05 月 12 日 ➢ 医药周观点：医药设备招投标持续复苏，重点关注血透、超声等细分领域国产替 代机遇。此外，连锁药房领域内随着中小厂商的陆续出清，龙头厂商有望借助行业加 速整合机遇迎来市占率提升。 ➢ 1）创新药：云顶新耀布地奈德肠溶胶囊获得 NMPA 完全批准，翰森制药阿美 替尼辅助适应症获批上市，建议关注国内外研发进展。2）CXO：国内需求逐步回暖， 海外需求平稳向上，且目前对关税政策免疫，看好板块龙头企业逐季度订单和报表的 持续兑现带来的估值修复，重点关注药明生物、药明康德、凯莱英和康龙化成。3） 中医药：中医药方面，后续建议关注与生育补贴息息相关的标的，例如具备儿科用药 布局的济川药业、葵花药业等。4）疫苗及血制品：持续看好静丙行业未来 3-5 年的 发展潜力，其次关注浆站数量变化及头部集中背景下吨浆利润提升驱动的行业上行周 期中潜在受益的龙头公司，重视重组人白的获批进程以及潜在的产业变革。疫苗方向 基本面整体承压但部分重点公司业绩边际改善，关注重点公司 24 年下游库存周期改 善带来的业绩拐点及 mcv4 疫苗 25 年市场拓展情况。5 ...

Core Insights - Berry Genomics reported a revenue of 1.078 billion yuan for 2024, a year-on-year decrease of 6.36% [1] - The company achieved a net loss attributable to shareholders of 192 million yuan, a reduction in loss by 54.96% year-on-year [1] - Basic earnings per share were -0.54 yuan, with a weighted average return on equity of -10.87% [1] Financial Performance - Total operating expenses for 2024 amounted to 488 million yuan, with sales expenses decreasing by 19.02% and management expenses slightly increasing by 5.05% [3] - Research and development expenses fell by 13.26%, while financial expenses decreased by 48.94% due to debt optimization [3] - Net cash flow from operating activities was 87.96 million yuan, a year-on-year decrease of 20.75% [3] Revenue Breakdown - In 2024, revenue from reagent sales was 475 million yuan, a slight increase of 2.05%, accounting for 44.10% of total revenue [3] - Medical testing services contributed 35.26%, while basic research services accounted for 15.07% [3] - Equipment sales and other businesses made up 3.77% and 1.81% respectively, indicating that reagent sales and medical testing services remain the main revenue pillars despite increased market competition [3] Strategic Developments - Berry Genomics focused on optimizing product structure to enhance gross margins, with new prenatal and newborn screening products launched in 2023 supporting long-term growth potential [3] - Research and development expenses for 2024 were 113 million yuan, representing 10.53% of revenue, with advancements in third-generation sequencing technology for thalassemia testing [3] - The company established a joint venture with Saudi Arabian Ajlan Brothers Medical Company in 2023, focusing on reproductive health testing in the Middle East, and continued to advance local laboratory construction and product implementation in 2024 [3]

5月8日，贝瑞基因今日收盘12.97元，上涨1.41%，最新市净率2.75，创13天以来新低，总市值45.85亿 元。 成都市贝瑞和康基因技术股份有限公司主营业务为以高通量测序技术为基础的基因检测服务和基因检测 相关的设备、试剂销售。公司主要产品为基础科研服务、医学检测服务、试剂及仪器。公司是少数通 过"产品+服务"的综合方案为各级医院、第三方医学实验室等医疗机构提供医学产品及服务的公司之 一，凭借NIPT项目的先发优势，不断多元化基因检测服务项目并适时进行产品化，凭借在临床应用需 求的洞察力和在临床进行商业推广的成功经验，确立了公司在遗传学领域的领导地位。公司自主研发 的、具有万级技术分辨率的cSMART液态活检技术已获得国内外专利，凭借该技术优势，确立了公司在 肿瘤学领域的领先地位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.18亿元，同比-22.08%；净利润-6462206.12 元，同比-178.47%，销售毛利率49.48%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)19贝瑞基因-22.14-23.832.7545.85亿行业平均 49.2047.654.59104.8 ...